1. Home
  2. BOLT vs PTLE Comparison

BOLT vs PTLE Comparison

Compare BOLT & PTLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLT
  • PTLE
  • Stock Information
  • Founded
  • BOLT 2015
  • PTLE 2013
  • Country
  • BOLT United States
  • PTLE Singapore
  • Employees
  • BOLT N/A
  • PTLE N/A
  • Industry
  • BOLT Biotechnology: Pharmaceutical Preparations
  • PTLE Oil Refining/Marketing
  • Sector
  • BOLT Health Care
  • PTLE Energy
  • Exchange
  • BOLT Nasdaq
  • PTLE Nasdaq
  • Market Cap
  • BOLT 16.8M
  • PTLE 16.4M
  • IPO Year
  • BOLT 2021
  • PTLE 2024
  • Fundamental
  • Price
  • BOLT $5.91
  • PTLE $0.27
  • Analyst Decision
  • BOLT Buy
  • PTLE
  • Analyst Count
  • BOLT 3
  • PTLE 0
  • Target Price
  • BOLT $50.00
  • PTLE N/A
  • AVG Volume (30 Days)
  • BOLT 26.0K
  • PTLE 28.2M
  • Earning Date
  • BOLT 08-12-2025
  • PTLE 02-21-2025
  • Dividend Yield
  • BOLT N/A
  • PTLE N/A
  • EPS Growth
  • BOLT N/A
  • PTLE N/A
  • EPS
  • BOLT N/A
  • PTLE N/A
  • Revenue
  • BOLT $3,638,000.00
  • PTLE $98,133,646.00
  • Revenue This Year
  • BOLT N/A
  • PTLE N/A
  • Revenue Next Year
  • BOLT $24.14
  • PTLE N/A
  • P/E Ratio
  • BOLT N/A
  • PTLE N/A
  • Revenue Growth
  • BOLT N/A
  • PTLE N/A
  • 52 Week Low
  • BOLT $5.20
  • PTLE $0.17
  • 52 Week High
  • BOLT $15.60
  • PTLE $15.78
  • Technical
  • Relative Strength Index (RSI)
  • BOLT 47.01
  • PTLE N/A
  • Support Level
  • BOLT $5.52
  • PTLE N/A
  • Resistance Level
  • BOLT $6.21
  • PTLE N/A
  • Average True Range (ATR)
  • BOLT 0.33
  • PTLE 0.00
  • MACD
  • BOLT 0.04
  • PTLE 0.00
  • Stochastic Oscillator
  • BOLT 48.67
  • PTLE 0.00

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

About PTLE PTL LTD Ordinary Shares

PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, primarily serving the Asia Pacific market. As a bunker facilitator, the Group's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers in a timely manner; and handling disputes, mainly in relation to quality and quantity issues on marine fuel, if any.

Share on Social Networks: